How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?

How has our knowledge of the safety and efficacy of PCSCK9 inhibitors evolved, and how has the ODYSSEY Outcomes “treat-to-target” trial helped us translate these advances into the front lines of interventional cardiology practice?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Phillipe Steg, MD

Phillipe Steg, MD

Professor of Cardiology
Université Paris – Diderot, Sorbonne-Paris Cité
Professor, National Heart and Lung Institute
Imperial College, London, UK
Director, Coronary Care Unit
Hôpital Bichat
Paris, France